Annual CFO
-$218.41 M
-$10.92 M-5.26%
31 December 2023
Summary:
REGENXBIO annual cash flow from operations is currently -$218.41 million, with the most recent change of -$10.92 million (-5.26%) on 31 December 2023. During the last 3 years, it has fallen by -$164.35 million (-304.00%). RGNX annual CFO is now -199.79% below its all-time high of $218.88 million, reached on 31 December 2021.RGNX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$40.55 M
+$4.95 M+10.88%
30 September 2024
Summary:
REGENXBIO quarterly cash flow from operations is currently -$40.55 million, with the most recent change of +$4.95 million (+10.88%) on 30 September 2024. Over the past year, it has increased by +$8.86 million (+17.93%). RGNX quarterly CFO is now -111.87% below its all-time high of $341.50 million, reached on 31 December 2021.RGNX Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$182.26 M
+$8.86 M+4.63%
30 September 2024
Summary:
REGENXBIO TTM cash flow from operations is currently -$182.26 million, with the most recent change of +$8.86 million (+4.63%) on 30 September 2024. Over the past year, it has increased by +$34.76 million (+16.02%). RGNX TTM CFO is now -183.27% below its all-time high of $218.88 million, reached on 31 December 2021.RGNX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RGNX Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -5.3% | +17.9% | +16.0% |
| 3 y3 years | -304.0% | +4.6% | -119.2% |
| 5 y5 years | -308.7% | -39.1% | -111.1% |
RGNX Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -199.8% | at low | -111.9% | +49.9% | -183.3% | +21.6% |
| 5 y | 5 years | -199.8% | at low | -111.9% | +49.9% | -183.3% | +21.6% |
| alltime | all time | -199.8% | at low | -111.9% | +49.9% | -183.3% | +21.6% |
REGENXBIO Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$40.55 M(-10.9%) | -$182.26 M(-4.6%) |
| June 2024 | - | -$45.50 M(-18.0%) | -$191.12 M(-0.9%) |
| Mar 2024 | - | -$55.45 M(+36.1%) | -$192.94 M(-11.7%) |
| Dec 2023 | -$218.41 M(+5.3%) | -$40.76 M(-17.5%) | -$218.41 M(+0.6%) |
| Sept 2023 | - | -$49.41 M(+4.4%) | -$217.02 M(-0.5%) |
| June 2023 | - | -$47.32 M(-41.5%) | -$218.07 M(-6.2%) |
| Mar 2023 | - | -$80.92 M(+105.5%) | -$232.50 M(+12.1%) |
| Dec 2022 | -$207.49 M(-194.8%) | -$39.37 M(-22.0%) | -$207.49 M(-219.7%) |
| Sept 2022 | - | -$50.46 M(-18.3%) | $173.38 M(-4.4%) |
| June 2022 | - | -$61.75 M(+10.4%) | $181.33 M(-12.4%) |
| Mar 2022 | - | -$55.91 M(-116.4%) | $207.01 M(-5.4%) |
| Dec 2021 | $218.88 M(-504.9%) | $341.50 M(-903.5%) | $218.88 M(-363.2%) |
| Sept 2021 | - | -$42.50 M(+17.8%) | -$83.15 M(+7.8%) |
| June 2021 | - | -$36.07 M(-18.1%) | -$77.11 M(+23.3%) |
| Mar 2021 | - | -$44.05 M(-211.6%) | -$62.53 M(+15.7%) |
| Dec 2020 | -$54.06 M(-49.8%) | $39.47 M(-208.3%) | -$54.06 M(-54.6%) |
| Sept 2020 | - | -$36.46 M(+69.6%) | -$119.03 M(+6.5%) |
| June 2020 | - | -$21.50 M(-39.6%) | -$111.73 M(-2.0%) |
| Mar 2020 | - | -$35.57 M(+39.5%) | -$113.98 M(+5.8%) |
| Dec 2019 | -$107.70 M | -$25.51 M(-12.5%) | -$107.70 M(+24.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2019 | - | -$29.15 M(+22.8%) | -$86.34 M(+12.5%) |
| June 2019 | - | -$23.75 M(-18.9%) | -$76.74 M(-545.7%) |
| Mar 2019 | - | -$29.30 M(+607.7%) | $17.22 M(-83.5%) |
| Dec 2018 | $104.65 M(-280.5%) | -$4.14 M(-78.8%) | $104.65 M(+10.2%) |
| Sept 2018 | - | -$19.56 M(-127.9%) | $94.96 M(-2.5%) |
| June 2018 | - | $70.21 M(+20.8%) | $97.38 M(+452.6%) |
| Mar 2018 | - | $58.13 M(-520.5%) | $17.62 M(-130.4%) |
| Dec 2017 | -$57.99 M(+19.4%) | -$13.83 M(-19.3%) | -$57.99 M(-10.2%) |
| Sept 2017 | - | -$17.14 M(+79.5%) | -$64.59 M(+9.0%) |
| June 2017 | - | -$9.55 M(-45.4%) | -$59.27 M(+1.9%) |
| Mar 2017 | - | -$17.48 M(-14.4%) | -$58.15 M(+19.8%) |
| Dec 2016 | -$48.56 M(+115.7%) | -$20.42 M(+72.8%) | -$48.56 M(+49.1%) |
| Sept 2016 | - | -$11.82 M(+40.2%) | -$32.58 M(+11.7%) |
| June 2016 | - | -$8.43 M(+6.9%) | -$29.16 M(+1.5%) |
| Mar 2016 | - | -$7.89 M(+77.5%) | -$28.73 M(+27.6%) |
| Dec 2015 | -$22.52 M(+838.5%) | -$4.44 M(-47.1%) | -$22.52 M(+24.6%) |
| Sept 2015 | - | -$8.39 M(+4.9%) | -$18.07 M(+86.8%) |
| June 2015 | - | -$8.00 M(+377.7%) | -$9.68 M(+477.7%) |
| Mar 2015 | - | -$1.68 M | -$1.68 M |
| Dec 2014 | -$2.40 M(-20.4%) | - | - |
| Dec 2013 | -$3.01 M | - | - |
FAQ
- What is REGENXBIO annual cash flow from operations?
- What is the all time high annual CFO for REGENXBIO?
- What is REGENXBIO annual CFO year-on-year change?
- What is REGENXBIO quarterly cash flow from operations?
- What is the all time high quarterly CFO for REGENXBIO?
- What is REGENXBIO quarterly CFO year-on-year change?
- What is REGENXBIO TTM cash flow from operations?
- What is the all time high TTM CFO for REGENXBIO?
- What is REGENXBIO TTM CFO year-on-year change?
What is REGENXBIO annual cash flow from operations?
The current annual CFO of RGNX is -$218.41 M
What is the all time high annual CFO for REGENXBIO?
REGENXBIO all-time high annual cash flow from operations is $218.88 M
What is REGENXBIO annual CFO year-on-year change?
Over the past year, RGNX annual cash flow from operations has changed by -$10.92 M (-5.26%)
What is REGENXBIO quarterly cash flow from operations?
The current quarterly CFO of RGNX is -$40.55 M
What is the all time high quarterly CFO for REGENXBIO?
REGENXBIO all-time high quarterly cash flow from operations is $341.50 M
What is REGENXBIO quarterly CFO year-on-year change?
Over the past year, RGNX quarterly cash flow from operations has changed by +$8.86 M (+17.93%)
What is REGENXBIO TTM cash flow from operations?
The current TTM CFO of RGNX is -$182.26 M
What is the all time high TTM CFO for REGENXBIO?
REGENXBIO all-time high TTM cash flow from operations is $218.88 M
What is REGENXBIO TTM CFO year-on-year change?
Over the past year, RGNX TTM cash flow from operations has changed by +$34.76 M (+16.02%)